As of 2025-05-31, the EV/EBITDA ratio of Bukwang Pharm Co Ltd (003000.KS) is 33.10. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. 003000.KS's latest enterprise value is 266,487.66 mil KRW. 003000.KS's TTM EBITDA according to its financial statements is 8,050.09 mil KRW. Dividing these 2 quantities gives us the above 003000.KS EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 13.8x - 21.1x | 19.3x |
| Forward P/E multiples | 9.3x - 15.3x | 12.4x |
| Fair Price | 793.83 - 2,595.65 | 1,704.20 |
| Upside | -80.2% - -35.2% | -57.4% |
| Date | EV/EBITDA |
| 2025-04-11 | 31.11 |
| 2025-04-10 | 31.02 |
| 2025-04-09 | 29.49 |
| 2025-04-08 | 30.17 |
| 2025-04-07 | 29.57 |
| 2025-04-04 | 31.36 |
| 2025-04-03 | 31.11 |
| 2025-04-02 | 31.66 |
| 2025-04-01 | 32.47 |
| 2025-03-31 | 32.17 |
| 2025-03-28 | 32.21 |
| 2025-03-27 | 37.31 |
| 2025-03-26 | 37.91 |
| 2025-03-25 | 37.91 |
| 2025-03-24 | 38.08 |
| 2025-03-21 | 38.63 |
| 2025-03-20 | 38.67 |
| 2025-03-19 | 38.29 |
| 2025-03-18 | 38.29 |
| 2025-03-17 | 38.25 |
| 2025-03-14 | 38.33 |
| 2025-03-13 | 37.95 |
| 2025-03-12 | 38.80 |
| 2025-03-11 | 38.80 |
| 2025-03-10 | 39.23 |
| 2025-03-07 | 39.14 |
| 2025-03-06 | 39.18 |
| 2025-03-05 | 39.01 |
| 2025-03-04 | 38.76 |
| 2025-02-28 | 39.78 |
| 2025-02-27 | 40.37 |
| 2025-02-26 | 41.56 |
| 2025-02-25 | 41.18 |
| 2025-02-24 | 41.52 |
| 2025-02-21 | 41.35 |
| 2025-02-20 | 41.56 |
| 2025-02-19 | 41.99 |
| 2025-02-18 | 42.07 |
| 2025-02-17 | 40.93 |
| 2025-02-14 | 39.65 |
| 2025-02-13 | 39.57 |
| 2025-02-12 | 39.57 |
| 2025-02-11 | 40.03 |
| 2025-02-10 | 39.44 |
| 2025-02-07 | 39.44 |
| 2025-02-06 | 39.82 |
| 2025-02-05 | 39.61 |
| 2025-02-04 | 38.63 |
| 2025-02-03 | 37.70 |
| 2025-01-31 | 38.89 |